Sexual health of women using combined oral contraceptive containing estetrol and drospirenone: A prospective observational study
| Autor: | Mekan R. Orazov, Viktor E. Radzinskiy, Marina B. Khamoshina, Roman E. Orekhov, Vasily V. Ermakov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Гинекология, Vol 26, Iss 1, Pp 28-34 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2079-5696 2079-5831 20795696 |
| DOI: | 10.26442/20795696.2024.1.202568 |
| Popis: | Aim. To evaluate the effect of a combined oral contraceptive (COC) containing estetrol and drospirenone on the sexual function of women using it. Materials and methods. A total of 251 women aged 21–35 years (mean age, 25.30±2.82 years) referred for contraceptive fitting were included in the study (ICD-10: Z30.0 General contraceptive advice and counseling, Z30.4 Contraceptive drug monitoring). Women in the study cohort used the original formulation containing 15 mg estetrol and 3 mg drospirenone in a 24+4 regimen for contraceptive purposes, according to the current instructions. All female participants (n=251) were assessed for sexual function at baseline, 6 and 12 months using FSFI (The Female Sexual Function Index), FSDS-R (The Female Sexual Distress Scale-Revised) and SQoL-F (The Sexual Quality of Life-Female) scales. Study design. An open, independent, prospective observational study. Results. Women taking COC containing estetrol 15 mg and drospirenone 3 mg maintained a baseline high level of sexual satisfaction (p0.05) throughout the study, as assessed by FSFI, SQoL-F and FSDS-R scales. Conclusion. The results obtained indicate that there is no negative effect of COC containing 15 mg estetrol and 3 mg drospirenonone on the sexual function of women. High contraceptive efficacy of the drug was confirmed. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|